Literature DB >> 25505075

Genetic analysis of the localization of APOBEC3F to human immunodeficiency virus type 1 virion cores.

John P Donahue1, Rebecca T Levinson2, Jonathan H Sheehan3, Lorraine Sutton1, Harry E Taylor4, Jens Meiler5, Richard T D'Aquila6, Chisu Song6.   

Abstract

UNLABELLED: Members of the APOBEC3 family of cytidine deaminases vary in their proportions of a virion-incorporated enzyme that is localized to mature retrovirus cores. We reported previously that APOBEC3F (A3F) was highly localized into mature human immunodeficiency virus type 1 (HIV-1) cores and identified that L306 in the C-terminal cytidine deaminase (CD) domain contributed to its core localization (C. Song, L. Sutton, M. Johnson, R. D'Aquila, J. Donahue, J Biol Chem 287:16965-16974, 2012, http://dx.doi.org/10.1074/jbc.M111.310839). We have now determined an additional genetic determinant(s) for A3F localization to HIV-1 cores. We found that one pair of leucines in each of A3F's C-terminal and N-terminal CD domains jointly determined the degree of localization of A3F into HIV-1 virion cores. These are A3F L306/L368 (C-terminal domain) and A3F L122/L184 (N-terminal domain). Alterations to one of these specific leucine residues in either of the two A3F CD domains (A3F L368A, L122A, and L184A) decreased core localization and diminished HIV restriction without changing virion packaging. Furthermore, double mutants in these leucine residues in each of A3F's two CD domains (A3F L368A plus L184A or A3F L368A plus L122A) still were packaged into virions but completely lost core localization and anti-HIV activity. HIV virion core localization of A3F is genetically separable from its virion packaging, and anti-HIV activity requires some core localization. IMPORTANCE: Specific leucine-leucine interactions are identified as necessary for A3F's core localization and anti-HIV activity but not for its packaging into virions. Understanding these signals may lead to novel strategies to enhance core localization that may augment effects of A3F against HIV and perhaps of other A3s against retroviruses, parvoviruses, and hepatitis B virus.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25505075      PMCID: PMC4338907          DOI: 10.1128/JVI.01981-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Comment on "Inhibition of hepatitis B virus replication by APOBEC3G".

Authors:  Christine Rösler; Josef Köck; Michael H Malim; Hubert E Blum; Fritz von Weizsäcker
Journal:  Science       Date:  2004-09-03       Impact factor: 47.728

2.  Inhibition of hepatitis B virus replication by APOBEC3G.

Authors:  Priscilla Turelli; Bastien Mangeat; Stephanie Jost; Sandrine Vianin; Didier Trono
Journal:  Science       Date:  2004-03-19       Impact factor: 47.728

3.  APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses.

Authors:  Cécile Esnault; Odile Heidmann; Frédéric Delebecque; Marie Dewannieux; David Ribet; Allan J Hance; Thierry Heidmann; Olivier Schwartz
Journal:  Nature       Date:  2005-01-27       Impact factor: 49.962

4.  The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain.

Authors:  Guylaine Haché; Mark T Liddament; Reuben S Harris
Journal:  J Biol Chem       Date:  2005-01-12       Impact factor: 5.157

5.  High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells.

Authors:  Yves Durocher; Sylvie Perret; Amine Kamen
Journal:  Nucleic Acids Res       Date:  2002-01-15       Impact factor: 16.971

6.  Small-molecule ligand docking into comparative models with Rosetta.

Authors:  Steven A Combs; Samuel L Deluca; Stephanie H Deluca; Gordon H Lemmon; David P Nannemann; Elizabeth D Nguyen; Jordan R Willis; Jonathan H Sheehan; Jens Meiler
Journal:  Nat Protoc       Date:  2013-06-06       Impact factor: 13.491

7.  Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases.

Authors:  James A Dutko; Alexandra Schäfer; Alison E Kenny; Bryan R Cullen; M Joan Curcio
Journal:  Curr Biol       Date:  2005-04-12       Impact factor: 10.834

8.  Association of Nef with the human immunodeficiency virus type 1 core.

Authors:  A Kotov; J Zhou; P Flicker; C Aiken
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

9.  Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.

Authors:  Yong-Hui Zheng; Dan Irwin; Takeshi Kurosu; Kenzo Tokunaga; Tetsutaro Sata; B Matija Peterlin
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Authors:  Bastien Mangeat; Priscilla Turelli; Gersende Caron; Marc Friedli; Luc Perrin; Didier Trono
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

View more
  4 in total

Review 1.  APOBECs and virus restriction.

Authors:  Reuben S Harris; Jaquelin P Dudley
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

2.  The in vitro Biochemical Characterization of an HIV-1 Restriction Factor APOBEC3F: Importance of Loop 7 on Both CD1 and CD2 for DNA Binding and Deamination.

Authors:  Qihan Chen; Xiao Xiao; Aaron Wolfe; Xiaojiang S Chen
Journal:  J Mol Biol       Date:  2016-04-08       Impact factor: 5.469

Review 3.  Multiple Inhibitory Factors Act in the Late Phase of HIV-1 Replication: a Systematic Review of the Literature.

Authors:  Jean-François Gélinas; Deborah R Gill; Stephen C Hyde
Journal:  Microbiol Mol Biol Rev       Date:  2018-01-10       Impact factor: 11.056

4.  Molecular Interactions of a DNA Modifying Enzyme APOBEC3F Catalytic Domain with a Single-Stranded DNA.

Authors:  Yao Fang; Xiao Xiao; Shu-Xing Li; Aaron Wolfe; Xiaojiang S Chen
Journal:  J Mol Biol       Date:  2017-11-27       Impact factor: 5.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.